ダウンロード数: 602

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
63_10_413.pdf1.11 MBAdobe PDF見る/開く
タイトル: 術後化学療法としてTS-1/CDDP 併用療法を施行した尿膜管癌の2例
その他のタイトル: Two Cases of Urachal Carcinoma Treated by TS-1/CDDP as Adjuvant Chemotherapy
著者: 小澤, 迪喜  KAKEN_name
黒本, 暁人  KAKEN_name
諸角, 謙人  KAKEN_name
佐藤, 真彦  KAKEN_name
星, 宣次  KAKEN_name
沼畑, 健司  KAKEN_name
著者名の別形: Ozawa, Michinobu
Kuromoto, Akito
Morozumi, Kento
Satou, Masahiko
Hoshi, Senji
Numahata, Kenji
キーワード: Urachal adenocarcinoma
Adjuvant chemotherapy
CDDP/TS-1
発行日: 31-Oct-2017
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要
巻: 63
号: 10
開始ページ: 413
終了ページ: 419
抄録: Case 1 : A 48-year-old man presenting with gross hematuria was suspected to have a tumor located in the bladder dome. He was referred to our department for further examination and treatment. Cystoscopy showed a dome-shaped mass in the supravesical region. Computed tomography and magnetic resonance imaging indicated the possibility of urachal carcinoma and peritoneal dissemination. Therefore, partial cystectomy with urachal resection was performed. The intraoperative findings were disseminated peritoneal nodules and mucus entering the peritoneal cavity from the tumor. On pathological examination, the tumor was classified as a mucinous-type adenocarcinoma, and 6 courses of TS-1/cisplatin (CDDP) therapy were administered to the patient as adjuvant chemotherapy. To date (10 months since the surgery), there has been no disease progression. Case 2 : A 76-year-old woman was referred to our department with a finding of a tumor in the bladder dome during her detailed examination for lung tumors. Cystoscopy showed nodular tumors, indicating lung metastases of the urachal carcinoma. Therefore, partial cystectomy with urachal resection was performed. On pathological examination, the tumor was classified as an enteric-type adenocarcinoma, and 2 courses of TS-1/CDDP therapy were administered to the patient as adjuvant chemotherapy. However, due to the development of marked bone marrow depression, the drugs had to be discontinued. Nonetheless, the lung metastases markedly diminished in size. To date (9 months since the discontinuation of chemotherapy), there has been no disease progression.
著作権等: 許諾条件により本文は2018/11/01に公開
DOI: 10.14989/ActaUrolJap_63_10_413
URI: http://hdl.handle.net/2433/227798
PubMed ID: 29103255
出現コレクション:Vol.63 No.10

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。